CervoMed to Participate in Upcoming Investor Conferences

Rhea-AI Summary

CervoMed Inc. (CRVO) announces participation in three investor conferences in April 2024 to discuss its developments in treating age-related neurologic disorders. The company's management will engage in Q&A sessions and corporate presentations, providing insights into their progress and future plans.

BOSTON, March 28, 2024 (GLOBE NEWSWIRE) -- CervoMed Inc. (NASDAQ: CRVO), a clinical stage company focused on developing treatments for age-related neurologic disorders, today announced that Company’s Management will participate in the following three investor conferences during the month of April:

Emerging Growth Conference 69
Format: Q&A Session
Date: Wednesday, April 3, 2024
Time: 3:25 PM ET
Webcast Link: click here

If attendees are not able to join the event live on the day of the conference, an archived webcast will also be made available on EmergingGrowth.com and on the Emerging Growth YouTube Channel, http://www.YouTube.com/EmergingGrowthConference. We will release a link to that after the event.

MedInvest Biotech & Pharma Investor Conference
Format: Corporate presentation
Date: Thursday, April 4, 2024
Time: 9:40 AM ET
Webcast Link: click here

To learn more about the MedInvest Biotech & Pharma Investor Conference please visit https://www.medinvestconferences.com/

23^rd Annual Needham Virtual Healthcare Conference
Format: Corporate presentation
Date: Thursday, April 11, 2024
Time: 12:45 PM ET
Webcast Link: click here

Available webcasts will be accessible in the Investor section of the CervoMed website https://www.cervomed.com/.

About CervoMed
CervoMed is a clinical-stage company focused on developing treatments for age-related neurologic disorders. The company is currently developing neflamapimod, an investigational orally administered small molecule brain penetrant that inhibits p38MAP kinase alpha (p38a). Neflamapimod has the potential to treat synaptic dysfunction, the reversible aspect of the underlying neurodegenerative processes that cause disease in DLB and certain other major neurological disorders. Neflamapimod is currently being evaluated in a Phase 2b study in patients with DLB.

Investor Contact:
PJ Kelleher
LifeSci Advisors
Investors@cervomed.com
617-430-7579

FAQ

When will CervoMed Inc. participate in the Emerging Growth Conference 69?

CervoMed Inc. will participate in the Emerging Growth Conference 69 on Wednesday, April 3, 2024, at 3:25 PM ET.

Where can I watch the webcast of the Emerging Growth Conference 69 if I miss the live event?

You can watch the archived webcast of the Emerging Growth Conference 69 on EmergingGrowth.com and the Emerging Growth YouTube Channel.

What is the date and time of CervoMed Inc.'s corporate presentation at the MedInvest Biotech & Pharma Investor Conference?

CervoMed Inc. will present at the MedInvest Biotech & Pharma Investor Conference on Thursday, April 4, 2024, at 9:40 AM ET.